Endra Life Sciences Inc (NDRA)

[biotech_researcher]

Dndodd, these are facts from NDRA's filings. Many of your posts are "hopeful thoughts" and not in the realm of science. Good luck to you with this investment.

[dndodd]

What “seems” right to you is obviously not reality.

[biotech_researcher]

"Is it just me or anyone else questioning the TAEUS' ability to accurately quantify liver fat. Read the clinical trial posted on their website. Seems to me that they are missing about 20% of patients with liver fat >6%. This explains a lot.....

[biotech_researcher]

Thank you derkamp

[dndodd]

You do not know if GE sees the value or not, pure supposition on your part.

[biotech_researcher]

dndodd, I expect you will know the true value before me. GE doesn’t see the value. This would be a rounding error on their tax return..

[dndodd]

The only persons I have come across that is qualified to answer your questions is someone from Endra or there is a poster on Stocktwits - GenomeGuru who I believe is qualified to give you a good answer.

[dndodd]

As much as I follow Endra I am not qualified to properly interpret the results of a clinical trial I rely on the investor presentation; https://s3.amazonaws.com/cdn.irdirect.net/PIR/957/4471/ENDRA%20Life%20Sciences%20Investor%20Presentation%20June%202020.pdf

It is my understanding TAEUS is very close to being as good as an MRI in quantifying liver fat which depending on who you talk to is considered the gold standard for liver fat. Other clinicians have said the liver biopsy is considered the gold standard but they may also be trying to check for fibrosis at the same time.

I found a you tube presentation on Liver Disease -The Silent epidemic By a Dr from UCSF to be very educational I believe her name is Danielle Brandman.
Beyond that reach out to Endra for answers they are generally very responsive.

[Sluicebox]

First time looking at this stick so excuse me if I got it wrong, but please explain
Is it just me or anyone else questioning the TAEUS' ability to accurately quantify liver fat. Read the clinical trial posted on their website. Seems to me that they are missing about 20% of patients with liver fat >6%. How does that work in real life. Wouldn't we simply just continue using biopsy and be sure ?

[Marksch1]

Im holding out for .80-.81 area and then low 60's if it really gets weak, hopefully it won't come to that.

[dndodd]

Great I don’t think anybody will get hurt at these prices. I am impressed after last weeks heavy volume day the price has held up better then I expected.

[derkampfer]

Added 12,000 shares today @ $.855.

This dip is an opportunity IMHO

GLTA

[dndodd]

Also means you probably know sqaut.

The relationships are deep with GE they have first right of refusal no need for them to be in hurry.

In addition I doubt we see any type of BO offer before FDA approval and a few sales.

[Marksch1]

I don't know. I was called a brave soul and much worse for loading up cydy sub 50 cents, im now wealthier than I ever thought I would be. Not saying that's gonna happen here, but as a potential lottery ticket, I'm willing to buy some shares.

[biotech_researcher]

That means GE values their IP as squat.

[biotech_researcher]

I expect the management team is working hard and doing the best they can. The crux of the problem is that they are running out of money. GE STILL does not see the need to purchase the company and its technology for essentially chicken scratch. That bothers me immensely..

[Tonyboons33]

List of insiders purchasing is also encouraging: https://fintel.io/n/us/ndra

[Tonyboons33]

Any reason to believe there's shady stuff going on or management team is not acting in best interest of shareholders? I keep hanging my hat on the fact that mgmt reduced their salaries by 33% when COVID hit the fan and that gave me confidence that they were legit and actually trying to do what's in the best interest of the company, to get TAEUS commercialized and to market. Any feedback here would be greatly appreciated. I still believe the future for this company is exceedingly bright, provided that the mgmt team is not a bunch of crooks.

[biotech_researcher]

Marksch1, brave soul as that would be following the path that Enron investors followed many years ago.. There is a reason it is $.80’s...

[Marksch1]

That's for sure. Im looking to add a bit at .80 and more at .60 if it keeps selling off.

[biotech_researcher]

Not acting well...

[Marksch1]

Yep that was interesting. Can't believe that wild ride on Thursday. Tell you one thing, if it falls back to the 60 cent area I will be adding

[dndodd]

https://podcasts.apple.com/us/podcast/612-rewards-customer-insight-david-wells-cfo-endra/id832481615?i=1000480895540

Interesting interview with David Wells CFO of Endra

[dndodd]

Yep in the eyes of myself and most financial professionals I have spoken with it is way undervalued for a company that is about to go to market with a disruptive product like TAEUS.

[Marksch1]

Isn't a 13 mil market cap pretty low for this outfit? That ultrasound addresses a huge market.

[Penny chatter]

Need to sustain and over 1.00 price imo.

[dndodd]

I know I have a friend who is in love with CYDY. I don't like all the insider sells and promises that it is a cure for many things and all the PR's. Glad you did well.


Hope we do better with NDRA.

[Marksch1]

The cydy thing I would challenge, although it's a moot point now. My average is 55 cents and I've sold a third of my shares at 7.50 and 9.95-- the rest of my shares may make me quite wealthy if the FDA approves for covid.
Best move in 40 years of trading/investing.
This one also looks interesting to me for whatever it's worth.

[dndodd]

https://fostersresearch.com/2020/07/02/endra-life-sciences-inc-ndra-got-you-down-better-days-are-ahead/


ENDRA Life Sciences Inc. (NDRA) Got You Down? Better Days Are Ahead
By
Wendy Andrews -
July 2, 2020

The stock of ENDRA Life Sciences Inc. (NASDAQ:NDRA) is now priced at $0.93 and the shares are -0.03 points down or -3.38% lower compared to its previous closing price of $0.96. The stock had 228253 contracts set over the past session. NDRA shares’ daily volume is compared to its average trading volume at 331438 shares. However, it has a float of 12.68 million and although its performance was -3.15% over the week, it’s one to watch. NDRA share price recently placing at $0.94 to $1.

The shorts are climbing into the ENDRA Life Sciences Inc. stock, with the latest data on short interest released on June 15, 2020, showing that short interest numbers in the NDRA shares have risen. Short interest in the stock represents just 4.89% of its float, but the volume has raised by 655. The volume of shorted shares rised to 620394 from 619739 shares over the last two weeks. The average intraday trading volume has been 335150 shares, which means that days to cover moved to roughly 1.851094.

In the last trading session, ENDRA Life Sciences Inc. (NASDAQ:NDRA) dropped by -$0.0302 over the week and lost -$0.0101 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $2.25. The stock recorded its established 52-week high on 01/06/20.

Since 04/06/20, the stock has traded to a low of $0.599 at 55.24%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 0. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.

Looking at current readings, ENDRA Life Sciences Inc.’s two-week RSI is 49.5. This suggests that the stock is neutral at the moment and that NDRA shares’ price movement remains stable. The stochastic readings are equally revealing at 44.48% meaning the NDRA share price is currently in neutral territory.

The technical chart shows that the NDRA stock will likely settle at between $0.963 and $0.9962 per share. However, if the stock dips below $0.9037, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $0.8776.

Currently, the stock is trading in the red of MACD, with a reading of -0.0173. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.

The average rating for the NDRA equity is 2 and is currently gathering a bullish momentum. Of 2 analysts tracking ENDRA Life Sciences Inc. polled by Reuters, 0 rated NDRA as a hold. The remaining 2 analysts were split evenly. However, the split wasn’t equal as a majority (2) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.

The stocks P/S ratio currently stands at 0below the group’s average of 55.4. ENDRA Life Sciences Inc. has its P/E ratio at 5.5, which means that the stock is currently trading at a premium relative to the 5.3 industry average.

TAGS
ENDRA Life Sciences Inc.
NASDAQ:NDRA
NDRA
NDRA news
NDRA stock

[dndodd]

All I saw on Stock Twits was something about a patent issued in February of 2020. After that was posted it took off, Looks to be another P & D. these will end on real news in the 6-9 months and this will be at least $4. IMO

[dndodd]

CYDY scares me as to the validity of their claims. This one doesn't at all.

[Penny chatter]

Looking good here

[Marksch1]

Volume is off the charts today. Anything happening??

[Marksch1]

Yeah. I bought a lottery ticket with this one using some of my cydy profits.

[dndodd]

Known event. Its surprises that will make a stock jump.

The challenge now is Europe and the problems trying to introduce the product with the virus issues like a 2 week quarantine.

The company has been very quiet on any plans in the Far East maybe they will start talking about that area of the world. Now that they have CE Mark and FDA application it is the next market. IMO.

Remember this is a disruptive technology.

[Marksch1]

Stock didn't exactly rally on the FDA news. What the heck?

[Shmoney1]

Pioneer in this arena of non invasive liver study with a system that can integrate into existing systems is huge.

[Tonyboons33]

I'm anxiously waiting, believe me. Have an uncomfortable position (for me) and believe in what I've read about the company.

[Shmoney1]

Just submitted to the fda yesterday. We hear back positively this flies. Mark it!

[Tonyboons33]

What stock are you looking at when you post these? We keep getting good news and getting pushed down under $1. I honestly don't understand it. The only explanation I can think of is there are enough trolls and people pumping it up as whenever there is good news it's up pre-market and then comes crashing back down. The % of shorts doesn't even seem to be high or an overwhelming number. I'm still long and hopeful as there's just so much potential with this company.

[SpaceManTrades]

Very nice dip opportunity here.

[Shmoney1]

Getting some volume here

[Penny chatter]

Popping back here

[Penny chatter]

Normal am dip then pop

[Penny chatter]

Looking good AH

[SpaceManTrades]

Indeed. I'm holding for 2 dollars or higher.

[SlappedSilly]

NDRA shaping job nicely

[Millimaker]

$1.20 break well on its way

[RedSox04]

Going to keep grabbing these lows

[Penny chatter]

Was expecting a pop on that news. Cheap here imo